V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213805 | 20080187 | 1.81 | 75.5 | Palliative (P) | 2017-05-14 | 2017-05-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101640304 |
| 20213806 | 20080188 | 0 | 51.5 | Palliative (P) | 2019-04-03 | 2019-04-03 | IMATINIB | 2 | N | IMATINIB | 100814932 |
| 20213807 | 20080189 | 1.6 | 78 | Curative (C) | 2017-03-22 | 2017-03-26 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101732783 |
| 20213808 | 20080190 | 1.77 | 61.7 | Neo-adjuvant (N) | 2016-02-12 | 2016-02-12 | IMATINIB | 02 | N | IMATINIB | 100170264 |
| 20213809 | 20080191 | 1.91 | 81.9 | Radical (R) | 2016-04-11 | 2016-04-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100273193 |
| 20213810 | 20080192 | 1.49 | 46 | Curative (C) | 2017-02-23 | 2017-02-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100740709 |
| 20213811 | 20080193 | 1.54 | 71.2 | Palliative (P) | 2017-03-16 | 2017-04-05 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100899857 |
| 20213812 | 20080194 | 1.65 | 75 | Palliative (P) | 2017-12-30 | 2018-01-04 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100079826 |
| 20213813 | 20080195 | 1.8 | 78.7 | Curative (C) | null | 2018-08-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101273695 |
| 20213814 | 20080196 | 1.6 | 59.9 | Palliative (P) | 2018-03-17 | 2018-04-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100681442 |
| 20213815 | 20080197 | 1.75 | 71.7 | Curative (C) | 2018-02-03 | 2018-03-03 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101652283 |
| 20213816 | 20080198 | 1.65 | null | Curative (C) | 2018-12-06 | 2018-12-09 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100601314 |
| 20213818 | 20080199 | 1.6 | 71.7 | null | 2016-05-17 | 2016-05-18 | LANREOTIDE | 02 | null | LANREOTIDE | 101727596 |
| 20213819 | 20080200 | 0 | 85.5 | 03 | 2019-06-30 | 2019-07-04 | LANREOTIDE | 02 | N | LANREOTIDE | 101044137 |
| 20213820 | 20080201 | 1.79 | 80.5 | Palliative (P) | 2016-02-16 | 2016-03-05 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101257716 |
| 20213822 | 20080203 | 1.67 | 95.4 | Palliative (P) | 2016-08-14 | 2016-09-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101583712 |
| 20213824 | 20080204 | 1.56 | 71.5 | 03 | 2018-03-27 | 2018-04-08 | HCX | 02 | N | IMATINIB | 101694751 |
| 20213825 | 20080205 | 1.65 | 97 | Curative (C) | 2019-11-21 | 2019-12-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100444315 |
| 20213827 | 20080206 | 1.62 | 71.3 | Palliative (P) | 2017-08-22 | 2017-08-23 | Trial Unspecified | 01 | N | TRIAL | 101794892 |
| 20213830 | 20080207 | 1.7 | 66.5 | null | 2018-01-25 | 2018-02-01 | HCX | 02 | null | IMATINIB | 101035103 |
| 20213831 | 20080208 | 1.68 | 0 | 03 | 2016-11-28 | 2016-11-28 | Imatinib 400mg | 99 | N | IMATINIB | 101864177 |
| 20213832 | 20080209 | 1.45 | 75 | Palliative (P) | 2019-09-28 | 2019-10-29 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101726376 |
| 20213833 | 20080210 | null | 91.4 | null | 2017-09-14 | 2017-09-14 | LANREOTIDE | 02 | null | LANREOTIDE | 100791515 |
| 20213834 | 20080211 | null | 109.6 | null | 2016-04-28 | 2016-04-28 | LANREOTIDE | 02 | null | LANREOTIDE | 100142916 |
| 20213836 | 20080213 | null | 80 | Curative (C) | 2016-06-19 | 2016-07-13 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100354298 |
| 20213837 | 20080214 | 1.7 | 86 | Palliative (P) | 2018-06-17 | 2018-06-24 | Trial Unspecified | Y | N | TRIAL | 101279137 |
| 20213838 | 20080215 | 1.88 | 0 | Palliative (P) | 2018-04-20 | 2018-04-23 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101210753 |
| 20213839 | 20080216 | 1.82 | 56.7 | Palliative (P) | 2016-11-06 | 2016-11-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101318907 |
| 20213840 | 20080217 | 1.57 | 89.9 | Palliative (P) | 2019-10-02 | 2019-10-21 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 100212374 |
| 20213842 | 20080218 | 1.52 | 65.8 | Palliative (P) | 2019-08-12 | 2019-08-16 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100632172 |
| 20213844 | 20080220 | 1.61 | 49.2 | Neo-adjuvant (N) | 2018-03-31 | 2018-04-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101203329 |
| 20213846 | 20080222 | 1.7 | 74 | null | 2018-02-09 | 2018-02-16 | LANREOTIDE | null | null | LANREOTIDE | 100406164 |
| 20213847 | 20080223 | 1.8 | 0 | Palliative (P) | 2017-08-06 | 2017-08-06 | Trial Unspecified | 01 | N | TRIAL | 100243171 |
| 20213848 | 20080224 | 1.68 | 100.7 | Palliative (P) | 2018-01-10 | 2018-01-19 | TCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100198663 |
| 20213849 | 20080225 | 1.73 | 76.1 | Curative (C) | 2016-05-13 | 2016-05-15 | HCX (Cape + Cisp + Tras) - Main | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100021650 |
| 20213851 | 20080227 | 1.53 | 0 | Neo-adjuvant (N) | 2016-08-30 | 2016-09-12 | IMATINIB | 02 | N | IMATINIB | 101775302 |
| 20213853 | 20080228 | 1.66 | 84.9 | Palliative (P) | 2018-07-11 | 2018-07-17 | Trial Unspecified | Y | N | TRIAL | 101530550 |
| 20213855 | 20080230 | 1.64 | 46.8 | null | null | 2019-12-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 101555883 |
| 20213856 | 20080231 | 1.63 | 86 | null | 2016-07-11 | 2016-07-11 | LANREOTIDE | 02 | null | LANREOTIDE | 101671389 |
| 20213857 | 20080232 | 1.8 | null | Palliative (P) | 2018-10-30 | 2018-11-10 | Trial Unspecified | 01 | N | TRIAL | 101345287 |
| 20213858 | 20080233 | null | null | Palliative (P) | 2017-07-01 | 2017-07-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100599641 |
| 20213859 | 20080234 | 1.7 | 70 | Disease modification (D) | 2018-01-22 | 2018-01-22 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 101276690 |
| 20213860 | 20080235 | 1.73 | null | Palliative (P) | 2018-03-13 | 2018-04-03 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101660189 |
| 20213861 | 20080236 | 1.79 | 53.6 | Palliative (P) | 2020-07-11 | 2020-07-11 | LANREOTIDE | 02 | N | LANREOTIDE | 100836532 |
| 20213862 | 20080237 | 1.88 | 83.1 | Palliative (P) | null | 2019-11-25 | GO2 TRIAL | 01 | N | TRIAL | 100264755 |
| 20213863 | 20080238 | 1.78 | 54.1 | Palliative (P) | 2018-02-10 | 2018-02-16 | Trial Unspecified | 1 | N | TRIAL | 100808881 |
| 20213864 | 20080239 | 1.78 | 68.1 | 03 | 2018-10-19 | 2018-10-19 | LANREOTIDE | N | N | LANREOTIDE | 100892143 |
| 20213865 | 20080240 | 1.8 | 85.5 | Neo-adjuvant (N) | 2020-03-22 | 2020-04-04 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101450607 |
| 20213866 | 20080241 | 1.72 | 87 | Palliative (P) | 2016-09-17 | 2016-10-04 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101602482 |
| 20213867 | 20080242 | 1.86 | 59 | Curative (C) | 2017-10-14 | 2017-11-03 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 100055309 |